Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the out-of-hospital setting (CONVINCE): a randomized clinical trial

Landi et al., Journal of Cardiovascular Medicine, doi:10.2459/JCM.0000000000001639, CONVINCE, NCT04516941
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization -4% Improvement Relative Risk Oxygen therapy -5% Analgesic need 40% Viral clearance 11% Colchicine  CONVINCE  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 59 patients in multiple countries No significant difference in outcomes seen c19early.org Landi et al., J. Cardiovascular Medicine, May 2024 Favorscolchicine Favorscontrol 0 0.5 1 1.5 2+
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020, now with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine treatments.
5,000+ studies for 104 treatments. c19early.org
Early terminated RCT with 14 colchicine, 13 edoxaban, 16 colchicine+edoxaban, and 16 control patients, showing no significant difference in outcomes with treatment up to 7 days after PCR diagnosis.
risk of hospitalization, 4.0% higher, RR 1.04, p = 0.98, treatment 30, control 29.
risk of oxygen therapy, 5.0% higher, RR 1.05, p = 0.97, treatment 30, control 29.
risk of analgesic need, 40.0% lower, RR 0.60, p = 0.97, treatment 30, control 29.
risk of no viral clearance, 11.0% lower, RR 0.89, p = 0.77, treatment 30, control 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Landi et al., 28 May 2024, Randomized Controlled Trial, multiple countries, peer-reviewed, 11 authors, trial NCT04516941 (history) (CONVINCE).
This PaperColchicineAll
{ 'indexed': {'date-parts': [[2024, 6, 4]], 'date-time': '2024-06-04T00:19:14Z', 'timestamp': 1717460354552}, 'reference-count': 7, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '7', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 7]]}, 'DOI': '10.2459/jcm.0000000000001639', 'type': 'journal-article', 'created': {'date-parts': [[2024, 5, 29]], 'date-time': '2024-05-29T11:04:55Z', 'timestamp': 1716980695000}, 'page': '565-568', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the ' 'out-of-hospital setting (CONVINCE): a randomized clinical trial', 'prefix': '10.2459', 'volume': '25', 'author': [ { 'given': 'Antonio', 'family': 'Landi', 'sequence': 'first', 'affiliation': [ {'name': 'Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC)'}, { 'name': 'Department of Biomedical Sciences, University of Italian ' 'Switzerland, Lugano, Switzerland'}]}, { 'given': 'Nuccia', 'family': 'Morici', 'sequence': 'additional', 'affiliation': [ { 'name': 'IRCCS S. Maria Nascente – Fondazione Don Carlo Gnocchi ONLUS, ' 'Milan, Italy'}]}, { 'given': 'Pascal', 'family': 'Vranckx', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Medicine and Life Sciences, Hasselt University, ' 'Hasselt, Belgium'}]}, { 'given': 'Enrico', 'family': 'Frigoli', 'sequence': 'additional', 'affiliation': [{'name': 'Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC)'}]}, { 'given': 'Luca', 'family': 'Bonacchini', 'sequence': 'additional', 'affiliation': [{'name': 'Emergency Department, ASST Great Metropolitan Hospital Niguarda'}]}, { 'given': 'Barbara', 'family': 'Omazzi', 'sequence': 'additional', 'affiliation': [{'name': 'Emergency Unit, ASST Rhodense, Garbagnate Milanese'}]}, { 'given': 'Moreno', 'family': 'Tresoldi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Unit of General Medicine and Advanced Care, IRCCS San Raffaele ' 'Hospital, Milan, Italy'}]}, { 'given': 'Claudio', 'family': 'Camponovo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesiology, Clinica Ars Medica, Genolier Swiss ' 'Medical Network, Gravesano'}]}, { 'given': 'Tiziano', 'family': 'Moccetti', 'sequence': 'additional', 'affiliation': [{'name': 'Studi Medici Riuniti & Partners, Lugano'}]}, { 'given': 'Stephan', 'family': 'Windecker', 'sequence': 'additional', 'affiliation': [{'name': 'Inselspital, University of Bern, Bern, Switzerland'}]}, { 'given': 'Marco', 'family': 'Valgimigli', 'sequence': 'additional', 'affiliation': [ {'name': 'Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC)'}, { 'name': 'Department of Biomedical Sciences, University of Italian ' 'Switzerland, Lugano, Switzerland'}, {'name': 'Inselspital, University of Bern, Bern, Switzerland'}]}], 'member': '276', 'published-online': {'date-parts': [[2024, 5, 28]]}, 'reference': [ { 'key': 'R1-20240603', 'doi-asserted-by': 'crossref', 'first-page': '1224', 'DOI': '10.1016/S0140-6736(22)01585-9', 'article-title': 'The Lancet Commission on lessons for the future from the COVID-19 ' 'pandemic', 'volume': '400', 'author': 'Sachs', 'year': '2022', 'journal-title': 'Lancet'}, { 'key': 'R2-20240603', 'doi-asserted-by': 'crossref', 'first-page': '893', 'DOI': '10.1007/s11739-020-02393-1', 'article-title': 'The burden of thrombotic complications in critically ill patients with ' 'COVID-19: charting the uncharted', 'volume': '15', 'author': 'Landi', 'year': '2020', 'journal-title': 'Intern Emerg Med'}, { 'key': 'R3-20240603', 'doi-asserted-by': 'crossref', 'first-page': '553', 'DOI': '10.1016/j.ajem.2020.07.045', 'article-title': 'Temporal trends in out-of-hospital cardiac arrest during the COVID-19 ' 'outbreak', 'volume': '45', 'author': 'Landi', 'year': '2021', 'journal-title': 'Am J Emerg Med'}, { 'key': 'R4-20240603', 'doi-asserted-by': 'crossref', 'first-page': '920', 'DOI': '10.2459/JCM.0000000000001556', 'article-title': 'Edoxaban and/or colchicine in outpatients with COVID-19: rationale and ' 'design of the CONVINCE trial', 'volume': '24', 'author': 'Landi', 'year': '2023', 'journal-title': 'J Cardiovasc Med (Hagerstown)'}, { 'key': 'R5-20240603', 'doi-asserted-by': 'crossref', 'first-page': 'e585', 'DOI': '10.1016/S2352-3026(22)00175-2', 'article-title': 'Enoxaparin for primary thromboprophylaxis in symptomatic outpatients ' 'with COVID-19 (OVID): a randomised, open-label, parallel-group, ' 'multicentre, phase 3 trial', 'volume': '9', 'author': 'Barco', 'year': '2022', 'journal-title': 'Lancet Haematol'}, { 'key': 'R6-20240603', 'doi-asserted-by': 'crossref', 'first-page': '1703', 'DOI': '10.1001/jama.2021.17272', 'article-title': 'Effect of antithrombotic therapy on clinical outcomes in outpatients ' 'with clinically stable symptomatic COVID-19: the ACTIV-4B Randomized ' 'Clinical Trial', 'volume': '326', 'author': 'Connors', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': 'R7-20240603', 'doi-asserted-by': 'crossref', 'first-page': '924', 'DOI': '10.1016/S2213-2600(21)00222-8', 'article-title': 'Colchicine for community-treated patients with COVID-19 (COLCORONA): a ' 'phase 3, randomised, double-blinded, adaptive, placebo-controlled, ' 'multicentre trial', 'volume': '9', 'author': 'Tardif', 'year': '2021', 'journal-title': 'Lancet Respir Med'}], 'container-title': 'Journal of Cardiovascular Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.2459/JCM.0000000000001639', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 6, 3]], 'date-time': '2024-06-03T18:01:48Z', 'timestamp': 1717437708000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.2459/JCM.0000000000001639'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 5, 28]]}, 'references-count': 7, 'journal-issue': {'issue': '7', 'published-print': {'date-parts': [[2024]]}}, 'URL': 'http://dx.doi.org/10.2459/JCM.0000000000001639', 'relation': {}, 'ISSN': ['1558-2027', '1558-2035'], 'subject': [], 'published': {'date-parts': [[2024, 5, 28]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit